Cellectar Biosciences, Inc. (CLRB): Total Liabilities
$5.06M
As of 2025-12-31
$6.77M
As of 2026-06-30
-25.1%
3-year compound annual growth
+5.5%
5-year compound annual growth
-1.6%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.06M | -48.4% | 2026-03-04, Balance as of period end |
| 2024-12-31 | $9.80M | -62.1% | 2026-03-04, Balance as of period end |
| 2023-12-31 | $25.85M | n/a | 2025-03-13, Balance as of period end |
| 2023-09-30 | $30.35M | n/a | 2024-10-29, Balance as of period end |
| 2023-06-30 | $13.52M | n/a | 2024-10-29, Balance as of period end |
| 2023-03-31 | $12.09M | n/a | 2024-10-29, Balance as of period end |
| 2022-12-31 | $12.05M | n/a | 2024-10-29, Balance as of period end |
| 2022-09-30 | $7.17M | n/a | 2024-10-29, Balance as of period end |
| 2022-06-30 | $6.60M | n/a | 2024-10-29, Balance as of period end |
| 2022-03-31 | $7.48M | n/a | 2024-10-29, Balance as of period end |
| 2021-12-31 | $4.16M | +7.6% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $3.86M | +21.1% | 2022-03-21, Balance as of period end |
| 2019-12-31 | $3.19M | +78.0% | 2021-03-02, Balance as of period end |
| 2018-12-31 | $1.79M | -15.3% | 2020-03-09, Balance as of period end |
| 2017-12-31 | $2.12M | +18.6% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $1.78M | -70.0% | 2018-03-21, Balance as of period end |
| 2015-12-31 | $5.95M | -11.5% | 2017-03-15, Balance as of period end |
| 2014-12-31 | $6.72M | +31.4% | 2016-10-20, Balance as of period end |
| 2013-12-31 | $5.12M | +287.7% | 2015-05-20, Balance as of period end |
| 2012-12-31 | $1.32M | n/a | 2014-03-19, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $5.06M | -48.4% |
| Cingulate Inc. (CING) | 2025-12-31 | $12.56M | +69.6% |
| Biovie Inc. (BIVI) | 2026-06-30 | $3.98M | +56.1% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $7.28M | -50.5% |
| Exicure, Inc. (XCUR) | 2025-12-31 | $10.12M | +22.1% |
| Actuate Therapeutics, Inc. (ACTU) | 2025-12-31 | $6.11M | -33.7% |
| CytoDyn Inc. (CYDY) | 2026-05-31 | $123.69M | +8.4% |
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $2.13M | -21.2% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $1.48M | -56.9% |
Compare CLRB, CING, BIVI, RVPH side by side · Screen every company in Pharmaceutical Preparations ↗